The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
Jaypirca is making waves in the fight against B-cell malignancies
A key highlight will be Brenntag’s qualified amino acids portfolio
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Subscribe To Our Newsletter & Stay Updated
